Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Surpasses Earnings Expectations and Shows Strong Revenue Growth

• Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) reported earnings of $0.13 per share in Q4 2025, beating the Zacks Consensus Estimate by +290.39%.
• The company's revenue reached $129.5 million in Q4 2025, an 84% increase from Q4 2024, with ZORYVE® generating $127.5 million in net product revenue.
• Arcutis raised its 2026 full-year net product sales guidance to between $480 million and $495 million, indicating strong future growth potential.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is a leading biopharmaceutical company dedicated to developing innovative treatments for dermatological conditions. The company has been making headlines in the medical community, especially with its flagship product ZORYVE® (roflumilast), which has demonstrated significant revenue growth. Operating within the competitive Zacks Medical - Biomedical and Genetics industry, Arcutis has consistently exceeded earnings expectations.

On February 26, 2026, H.C. Wainwright reaffirmed its "Buy" rating for ARQT, setting the stock price at $27.01 and raising the price target to $34, according to StreetInsider. This optimistic outlook is supported by Arcutis's robust financial performance in Q4 2025, where the company announced earnings of $0.13 per share, significantly surpassing the Zacks Consensus Estimate of $0.03 per share. This resulted in an extraordinary earnings surprise of +290.39%.

The company's revenue performance has also been noteworthy. Arcutis generated $129.5 million in revenue for Q4 2025, outperforming the Zacks Consensus Estimate by 11.93%. This marks a substantial increase from the $71.36 million reported in the same quarter of the previous year. Specifically, the net product revenue for ZORYVE® reached $127.5 million in Q4 2025, an 84% increase from Q4 2024 and a 29% rise from Q3 2025.

Beyond financial growth, Arcutis is actively expanding its product portfolio. The company recently announced positive topline data from the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% for children with mild to moderate atopic dermatitis. A Supplemental New Drug Application (sNDA) submission is expected in Q2 2026, signaling potential future growth avenues.

Arcutis is enhancing its dermatology sales force and initiating a targeted commercialization strategy focused on primary care and pediatric healthcare providers. The company achieved positive operating cash flow in Q4 2025 and anticipates maintaining this trend quarterly. With the upward revision of its 2026 full-year net product sales guidance to between $480 million and $495 million, Arcutis demonstrates confidence in its continued growth trajectory.